<DOC>
	<DOC>NCT02030925</DOC>
	<brief_summary>This study is meant to assess the effect of IW-3718 as an added treatment to ongoing once-daily protocol pump inhibitor (PPI) treatment for patients who continue to experience symptoms of their gastroesophageal reflux disease (GERD).</brief_summary>
	<brief_title>Ph2a Study to Evaluate IW-3718 in Patients With Gastroesophageal Reflux Not Completely Responsive to Proton Pump Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Proton Pump Inhibitors</mesh_term>
	<criteria>Patient is between 18 and 65 years of age at the Screening Visit; females must not be pregnant or must not be breastfeeding; Patient has a confirmed diagnosis of gastroesophageal reflux disease, must be currently taking a proton pump inhibitor (PPI), and must be experiencing GERD symptoms as specified by the protocol. Patient may not meet any of the excluded conditions specified in the protocol; Patient is experiencing alarm symptoms such as GI bleeding, anemia, vomiting, dysphagia, or unexpected weight loss; Patient has a clinically significant hypersensitivity or allergies to any of the active ingredients or excipients in the study medication.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>